Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, et al. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2016;22(6):1510-9.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, et al. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget. 2016;7(51):84675-84687.

Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, et al. Corrigendum: Stromal contribution to the colorectal cancer transcriptome. Nat Genet. 2016;48(10):1296.

Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson S-, et al. Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis. 2016;37(3):262-8.

Huh SJ, Oh H, Peterson MA, Almendro V, Hu R, Bowden M, et al. The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women. Cancer Res. 2016;76(7):1926-34.

Soshnev AA, Josefowicz SZ, C Allis D. Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome. Mol Cell. 2016;62(5):681-94.

Simms A, Jacob RP, Cohen C, Siddiqui MT. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility. Diagn Cytopathol. 2016;44(1):26-31.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, et al. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016;2(2):165-202.

Totonchy J, Cesarman E. Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy? Curr Opin Virol. 2016;20:71-77.

Sarwar M, Semenas J, Miftakhova R, Simoulis A, Robinson B, Wingren AG, et al. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells. Oncotarget. 2016;7(39):63065-63081.